The PROTAC CDK9 degrader-2 is primarily utilized in targeted protein degradation, a cutting-edge approach in drug discovery and therapeutic development. It functions by selectively degrading cyclin-dependent kinase 9 (CDK9), a protein implicated in various diseases, particularly cancer. By degrading CDK9, it disrupts abnormal cell proliferation and survival pathways, making it a promising candidate for cancer treatment, especially in malignancies where CDK9 overexpression plays a critical role. Additionally, it is being explored in research to better understand the role of CDK9 in transcriptional regulation and its potential as a therapeutic target in other diseases, such as viral infections and inflammatory disorders. Its application extends to preclinical studies, where it serves as a tool to validate CDK9 as a druggable target and to assess the efficacy of protein degradation strategies in disease models.